^
    3d
    Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    9d
    A Phase II Study of Triple-negative Breast Cancer Brain Metastases. (clinicaltrials.gov)
    P2, N=35, Recruiting, Fudan University | Unknown status --> Recruiting | N=59 --> 35 | Trial completion date: Jan 2022 --> May 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • adebrelimab (SHR-1316)
    9d
    A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (clinicaltrials.gov)
    P2, N=38, Recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    capecitabine • chiauranib (CS 2164)
    11d
    Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase-II clinical study (ChiCTR1900023776)
    P=N/A, N=120, Completed, Southwest Hospital, Army Medical University; Southwest Hospital, Army Medical University | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    lobaplatin (D19466)
    11d
    A randomized controlled phase II clinical trial comparing neoadjuvant TP (docetaxel + cisplatin) with TAC (docetaxel + adriamycin + cyclophosphamide) regimen in the treatment of operable triple negative breast cancer (ChiCTR1800019501)
    P2, N=212, Completed, He'nan Cancer Hospital; He'nan Cancer Hospital | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    cisplatin • docetaxel • doxorubicin hydrochloride • cyclophosphamide
    11d
    A randomized, controlled, single-center clinical trial assessing the efficacy and safety of pegylated liposomal doxorubicin combined with docetaxel versus epirubicin combined with docetaxel in neoadjuvant treatment of triple-negative breast cancer (ChiCTR2000040585)
    P2/3, N=156, Completed, Southwest Hospital, Army Medical University; Southwest Hospital, Army Medical University | Not yet recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    pegylated liposomal doxorubicin • epirubicin
    11d
    The metabolic regulative mechanisms and functions study on neoadjuvant chemotherapy resistance in early breast cancer (ChiCTR2400080523)
    P=N/A, N=50, Not yet recruiting, Peking University Cancer Hospital (Beijing Institute for Cancer Research); Peking University Cancer Hospital (Beijing Institute for Cancer Research)
    New trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    11d
    Neoadjuvant weekly utidelone combined with cisplatin in breast cancer: a prospective, multi-center study (URANIA) (ChiCTR2400084686)
    P2, N=143, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • Perjeta (pertuzumab) • utidelone IV (UTD1)
    11d
    Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China. (PubMed, J Cancer)
    Ultimately, we identified a unique cancer-related gene mutation profile and a subset of genes associated with primary resistance to trastuzumab and RFS in patients with HER2+/HR- breast cancer in Northwest China. These findings could lay the groundwork for future studies aimed at elucidating the mechanisms of resistance to trastuzumab and improving HER2-targeted treatment strategies.
    Clinical data • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • TOP2A (DNA topoisomerase 2-alpha) • FGFR4 (Fibroblast growth factor receptor 4) • CDK12 (Cyclin dependent kinase 12) • FAT1 (FAT atypical cadherin 1) • FANCA (FA Complementation Group A) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • STAG2 (Stromal Antigen 2) • EPAS1 (Endothelial PAS domain protein 1) • KMT2B (Lysine Methyltransferase 2B) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin)
    |
    Herceptin (trastuzumab)
    17d
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    methotrexate IV
    17d
    Neratinib in Combination With Ruxolitinib in Patients With mTNBC (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Baylor Research Institute | Initiation date: Nov 2023 --> Aug 2024
    Trial initiation date • Combination therapy • Metastases
    |
    ER (Estrogen receptor)
    |
    Nerlynx (neratinib) • Jakafi (ruxolitinib)
    17d
    Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer (clinicaltrials.gov)
    P2, N=26, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> May 2024 | Trial primary completion date: Jan 2025 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    dasatinib
    18d
    TORCHLIGHT: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (clinicaltrials.gov)
    P3, N=531, Active, not recruiting, Shanghai Junshi Bioscience Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    22d
    Ferritin and Serum Iron in a Causal Relationship with Estrogen Receptor-Negative Breast Cancer: a Two-Sample Mendelian Randomization Study. (PubMed, Clin Lab)
    Ferritin is positively correlated with ER-negative breast cancer, while serum iron is negatively associated with ER-negative breast cancer. However, there is no causal relationship between the four iron statuses and ER-positive breast cancer.
    Journal • Causal relationship
    |
    ER (Estrogen receptor)
    22d
    Vaccination of Triple Negative Breast Cancer Patients (clinicaltrials.gov)
    P1/2, N=16, Completed, University of Arkansas | N=24 --> 16
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    25d
    Genetic susceptibility to breast cancer increases the risk of neutropenia and agranulocytosis: insights from Mendelian randomization. (PubMed, Support Care Cancer)
    Our study provides genetic evidence for a causal association between breast cancer and its estrogen receptor subtypes and neutropenia. In clinical practice, in addition to focusing on therapeutic factors, additional attention should be given to breast cancer patients to avoid severe neutropenia.
    Journal
    |
    ER (Estrogen receptor)
    28d
    Amplicon 8p11.2-p12-based prediction of survival in breast cancer patients – is FGFR1 the driver gene? (ECP 2024)
    Conclusion In breast cancer, the 8p11.2-p12 amplicon shows clinically relevant gene expression profiles which could serve as potential targets for precision medicine in breast cancer patients. Moreover, the identified 7-gene minimal amplicon could be used as prognostic predictor for long-term survival.
    Clinical
    |
    FGFR1 (Fibroblast growth factor receptor 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • BAG4 (BAG Cochaperone 4) • ZNF703 (Zinc Finger Protein 703)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    29d
    NOSH-aspirin (NBS-1120) inhibits estrogen receptor negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways. (PubMed, J Pharmacol Exp Ther)
    The induction of reactive oxygen species and subsequent downregulation of FOXM1 represents a plausible mechanism contributing to the observed decrease in cell proliferation and concurrent increase in apoptosis. NOSH-ASA demonstrated a remarkable reduction in tumor size by 90% without inducing any observable gross toxicity, underscoring its promising translational potential.
    Preclinical • Journal
    |
    ER (Estrogen receptor) • CCND1 (Cyclin D1) • FOXM1 (Forkhead Box M1) • PCNA (Proliferating cell nuclear antigen) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    aspirin
    29d
    A case of irAE colitis caused by atezolizumab (JBCS 2024)
    We report a case of metastatic breast cancer in which the patient achieved partial response with atezolizumab plus nab-PTX, but developed colitis due to irAE, and then developed cytomegalovirus (CMV) colitis due to steroid treatment...Ganciclovir was started, and symptoms improved, and PSL was gradually tapered, and treatment was completed on day 243...In this case, CMV colitis occurred concomitantly, and it took some time before breast cancer treatment could be resumed. Although this is an irAE that occurs infrequently, it is considered necessary to pay attention to the progression of gastrointestinal symptoms and cooperate with gastroenterology from an early stage
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • albumin-bound paclitaxel
    29d
    Current status of HER2 companion diagnostics for the use of T-DXd in our hospital and our experience with the use of T-DXd for HER2-low expressing breast cancer (JBCS 2024)
    Of the 51 cases, 15 (29%) were HER2 0, 30 (59%) were 1+, and 6 (12%) were 2+. Of the 36 cases with low HER2 expression, 18 (60%) were ER positive/ER negative/12 (40%). One case was originally HER2 0 but changed to HER2 low expression, and conversely, 8 cases changed from low expression to HER2 0, with a concordance rate of HER2 status of 87.5% for HER2 0 and 73% for low expression.
    Clinical • Companion diagnostic
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    29d
    Perioperative experience with pembrolizumab in our hospital (JBCS 2024)
    After starting pembrolizumab + carboplatin (CBDCA) + weekly-paclitaxel (wPTX), she developed fatigue, nausea, and loss of appetite...When using them, it is necessary to pay close attention to immune-related adverse events, which are a concept different from the adverse events of conventional cytotoxic antitumor drugs. In addition, in cases such as Case 2, it is difficult to choose the postoperative therapy
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Kadcyla (ado-trastuzumab emtansine)
    29d
    Treatment experience of Trastuzumab Deruxtecan (T-Dxd) for metastatic and recurrent breast cancer with low HER2 expression in our hospital (JBCS 2024)
    Eight patients were hormone receptor (HR) positive and HER2 negative, four were HR negative and HER2 negative, four were stage IV, and eight were recurrent cases. The median number of lines of T-Dxd treatment for metastatic or recurrent breast cancer was five (2-12), with only one patient receiving the second line and 11 receiving the third line or later. The maximum therapeutic effect was PR in 3 patients, SD in 3 patients, PD in 3 patients, and NE in 3 patients.
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    29d
    Efficacy of trastuzumab decrustecan in patients with HER2 low-expressing breast cancer (JBCS 2024)
    Background Trastuzumab decrustecan has been shown to be effective in treating patients with HER2 low-expressing breast cancer. All 18 patients were female, with a median age of 62 years (44-75 years), 2 patients (11.1%) were premenopausal, and 16 patients (88.9%) were postmenopausal. Thirteen cases (72.2%) were recurrent, five cases (27.8%) were de novo Stage IV, 16 cases (88.9%) had visceral metastases, and three cases (16.7%) had brain metastases. Biology: 14 cases (77.8%) were hormone receptor (HR) positive, four cases (22.2%) were HR negative, and 14 cases (77.8%) were HER2 1+ and four cases (22.2%) were HER2 2+ by companion diagnosis using HER2 4B5.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    29d
    Clinical characteristics of HER2 low-expressing breast cancer in our department (JBCS 2024)
    Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that combines trastuzumab, an anti-human epidermal growth factor receptor type 2 (HER2) humanized monoclonal antibody, with deruxtecan, a topoisomerase I inhibitor...There were 6 cases of IHC 0, and all cases were judged to be 4B5 0. Previous reports have shown that 59.3-66.7% of HER2-negative breast cancers have low HER2 expression, which is generally consistent with the results
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    29d
    Clinical-pathological study of HER2-low expressing breast cancer in our department (JBCS 2024)
    Of the 327 cases, 51 (16%) were HER2 negative, 200 (61%) were HER2 low expression, 58 (18%) were HER2 positive, and 18 (5%) were HER2 low expression or positive. By hormone receptor status, of the 243 HR positive cases, 29 (12%) were HER negative, 171 (70%) were HER2 low expression, 27 (11%) were HER2 positive, and 16 (7%) were HER2 low expression or positive. Of the 84 HR-negative cases, 22 (26%) were HER2-negative, 29 (35%) were HER2-low expressing, 31 (37%) were HER2-positive, and 2 (2%) were either HER2-low expressing or positive.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    29d
    Epigenomic analysis of ctDNA testing for recurrence risk assessment at the time of breast cancer diagnosis (JBCS 2024)
    In postoperative recurrence cases, ctDNA showed a high positive rate from the time of initial diagnosis, suggesting that epigenetic analysis targeting methylation mutations is important in non-TIA cases
    Genomic analysis • Circulating tumor DNA • Omic analysis
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    GuardantREVEAL
    29d
    Examination of gene expression in breast cancer with 1% to 10% estrogen or progesterone receptor positive immunohistochemical staining (JBCS 2024)
    These reports that the majority of IHC ER and low PgR expression cases have genetic characteristics of hormone receptor-negative were all published in the early 2010s, but more than 10 years have passed since then, and additional reports have been published, and the clinical significance is becoming clear. Based on these findings, we will clarify the characteristics of IHC ER and low PgR expression breast cancer and future prospects
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    30d
    Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    paclitaxel • Xofigo (radium Ra-223 dichloride)
    1m
    BRAF Expression and Copy Number Alterations Predict Unfavorable Tumor Features and Adverse Outcomes in Patients With Breast Cancer. (PubMed, Int J Breast Cancer)
    High BRAF mRNA expression as well as the gain and high-level amplification copy numbers were associated with advanced tumor characteristics and unfavorable prognostic factors in breast cancer. BRAF could be an appealing target for the treatment of premenopausal patients with hormone receptor-negative breast cancer.
    Journal • Adverse events
    |
    BRAF (B-raf proto-oncogene)
    1m
    Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers. (PubMed, Ann Oncol)
    In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive vs. negative disease warrants consideration in counseling patients on treatment, follow-up, and risk-reducing surgery.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    1m
    QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. (PubMed, Br J Cancer)
    QL1209 demonstrated equivalent efficacy and comparable safety profile to the reference pertuzumab in neoadjuvant treatment of HER2-positive, ER/PR-negative, early, or locally advanced breast cancer.
    Clinical • P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • QL1209 (pertuzumab biosimilar)
    1m
    ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Filipa Lynce, MD | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2024
    Enrollment open • Trial initiation date • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)
    1m
    TWIST1 Drives Cytotoxic CD8+ T-Cell Exhaustion through Transcriptional Activation of CD274 (PD-L1) Expression in Breast Cancer Cells. (PubMed, Cancers (Basel))
    These results demonstrate that TWIST1 directly induces PD-L1 expression in ERα-negative breast cancer cells to promote immune evasion. Targeting TWIST1, BRD8, and/or PD-L1 in ERα-negative breast cancer cells with TWIST1 expression may sensitize CD8+ T-cell-mediated immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TWIST1 (Twist Family BHLH Transcription Factor 1)
    1m
    SASCIA: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (clinicaltrials.gov)
    P3, N=1332, Active, not recruiting, German Breast Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    cisplatin • carboplatin • capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    1m
    Protein arginine methyltransferase CARM1 in human breast cancer. (PubMed, Endocrinology)
    The methyltransferase activity of CARM1 is important for many of its functions, herein, we also highlight the non-enzymatic roles of CARM1. We also cover the biological processes regulated by CARM1 that are often deregulated in cancer and the ways to harness CARM1 in cancer treatment.
    Journal
    |
    ER (Estrogen receptor)
    1m
    Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) (clinicaltrials.gov)
    P3, N=1157, Active, not recruiting, AstraZeneca | Trial primary completion date: Mar 2025 --> Jul 2025
    Trial primary completion date • Metastases
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    2ms
    OSU-16288: Nipple Aspirate Fluid in Detecting Breast Cancer (clinicaltrials.gov)
    P=N/A, N=2, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=100 --> 2 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) (clinicaltrials.gov)
    P3, N=878, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Jun 2025 | Trial primary completion date: Mar 2023 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide
    2ms
    Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    paclitaxel • Xofigo (radium Ra-223 dichloride)
    2ms
    DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (clinicaltrials.gov)
    P2, N=116, Completed, Prof. Wolfgang Janni | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date • Tumor cell • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Kisqali (ribociclib) • Halaven (eribulin mesylate)
    2ms
    Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China. (PubMed, PeerJ)
    Its reduced pCR rate in HR-positive subgroup is particularly important for clinical decisions. However, HER2-low is not a reliable factor for assessing long-term survival outcomes.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    2ms
    NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=782, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Oct 2026 | Trial primary completion date: Nov 2024 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide